19 July 2010 - Antitope Ltd. today announced a research collaboration with PIKAMAB, Inc. ("PIKAMAB") whereby Antitope will apply its proprietary EpiScreenTM technology to profile the immunogenicity of a series of biologics developed by PIKAMAB for the personalized treatment of cancers and autoimmune diseases. “We are delighted to be working with PIKAMAB who is an emerging leader in stratified medicine for the development of more efficacious biologics” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "We are confident that the addition of EpiScreenTM to other preclinical assays will assist PIKAMAB in their selection of customized therapeutic antibodies with low immunogenicity potential."
”We are very pleased to collaborate with Antitope as its EpiscreenTM technology is the most validated to determine the immunogenicity profiles of therapeutic antibodies a priori,” commented Vijay Ramakrishnan, President and CEO of PIKAMAB.
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit;
http://www.antitope.co.uk or contact:
Dr. Neil Butt
Business Development Director, Antitope Ltd.
Tel: +44 (0)1223 496190
An emerging industry leader in stratified medicine, PIKAMAB (pronounced Pick-a-MAb) is a biopharmaceutical company focused on developing efficacious therapeutic antibodies and theragnostic products to better treat cancers, autoimmune diseases, and inflammatory disorders. Through our proprietary patient stratification methods, we can improve the clinical trial outcomes of several antibody candidates currently in clinical development, and help achieve superior therapeutic outcomes for marketed antibody therapies. For more information, visit www.pikamab.com or contact:
Vijay Ramakrishnan, Ph.D.
Tel: +1 (650) 566-8344